ProQR Therapeutics (PRQR) News Today $2.56 -0.02 (-0.78%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.57 +0.01 (+0.55%) As of 02/21/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50 Day Moving Average - Here's WhyFebruary 20 at 7:15 AM | marketbeat.comAnalyzing ProQR Therapeutics (NASDAQ:PRQR) and Avadel Pharmaceuticals (NASDAQ:AVDL)February 16, 2025 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) Financial SurveyFebruary 13, 2025 | americanbankingnews.comJones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy RecommendationFebruary 12, 2025 | msn.comJones Trading sets ProQR stock Buy rating, $11 price targetFebruary 11, 2025 | msn.comProQR Therapeutics initiated with a Buy at JonesResearchFebruary 11, 2025 | markets.businessinsider.comProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%February 11, 2025 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by BrokeragesShares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buyJanuary 31, 2025 | marketbeat.comCantor Fitzgerald Predicts PRQR FY2025 EarningsProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ProQR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutiJanuary 22, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 918,100 shares, an increase of 151.7% from the December 15th total of 364,700 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 0.6 days.January 14, 2025 | marketbeat.comProQR’s Strategic Focus on RNA Editing for Liver Disease: Targeting PNPLA3 in the MASH SpaceJanuary 13, 2025 | markets.businessinsider.comProQR Therapeutics initiated with an Outperform at OppenheimerJanuary 10, 2025 | markets.businessinsider.comOppenheimer Begins Coverage on ProQR Therapeutics (NASDAQ:PRQR)Oppenheimer assumed coverage on ProQR Therapeutics in a research report on Friday. They set an "outperform" rating and a $15.00 target price for the company.January 10, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by AnalystsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given an average rating of "Buy" by the five analysts that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the coJanuary 6, 2025 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for ProQR Therapeutics (NASDAQ:PRQR)JMP Securities restated a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Buy Rating at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR’s Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics announces $8.1M in new funding from RSRTDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic PartnershipsDecember 11, 2024 | tipranks.comProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing CollaborationDecember 11, 2024 | markets.businessinsider.comProQR Therapeutics appoints Beal as Chief ADAR ScientistDecember 10, 2024 | tipranks.comProQR Appoints Peter A. Beal, PhD, as Chief ADAR ScientistDecember 10, 2024 | globenewswire.comProQR Therapeutics price target raised to $8 from $5 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comProQR Highlights RNA Innovations in Upcoming EventDecember 5, 2024 | tipranks.comProQR Therapeutics Highlights Q3 2024 Financial ResultsNovember 21, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?November 21, 2024 | marketbeat.comWhat is Chardan Capital's Forecast for PRQR FY2024 Earnings?ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Chardan Capital decreased their FY2024 earnings per share estimates for shares of ProQR Therapeutics in a report released on Sunday, November 10th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.31)November 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00HC Wainwright raised their target price on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday.November 8, 2024 | marketbeat.comProQR Therapeutics price target raised to $10 from $5 at H.C. WainwrightNovember 8, 2024 | tipranks.comProQR Announces Third Quarter 2024 Operating and Financial ResultsNovember 8, 2024 | markets.businessinsider.comProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last yearNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics Shows Revenue Growth Amid Financial ChallengesNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above Fifty Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comRaymond James Upgrades ProQR Therapeutics N.V. (PRQR)October 29, 2024 | msn.comProQR Therapeutics (NASDAQ:PRQR) Upgraded to Strong-Buy at Raymond JamesRaymond James upgraded ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $6.00 to $14.00 in a research report on Tuesday.October 29, 2024 | marketbeat.comProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementOctober 25, 2024 | globenewswire.comProQR Therapeutics 18M share Spot Secondary priced at $3.50October 24, 2024 | markets.businessinsider.comProQR Therapeutics announces ordinary shares offering, no amount givenOctober 23, 2024 | markets.businessinsider.comProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementOctober 22, 2024 | globenewswire.comProQR Announces Proposed Underwritten Public Offering of Ordinary SharesOctober 22, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 yearOctober 21, 2024 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Stock Quotes, Forecast and News SummaryOctober 17, 2024 | benzinga.comProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyOctober 7, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below 200 Day Moving Average - Here's WhyOctober 5, 2024 | marketbeat.comAutolus Therapeutics plc (6A3A.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $1.90September 10, 2024 | marketbeat.comPRQR ProQR Therapeutics N.V.September 4, 2024 | seekingalpha.comProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼0.000.60▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼21▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News Today Prothena News Today Cronos Group News Today GH Research News Today Bicara Therapeutics News Today Verve Therapeutics News Today Mind Medicine (MindMed) News Today Dianthus Therapeutics News Today Anavex Life Sciences News Today Opthea News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRQR Stock Alerts